Global Competitiveness Report

Global Blood Pressure Monitoring Devices Market Report to 2027 - Featuring A&D Medical, GE Healthcare, Welch Allyn and Schiller Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Medical Devices, Health, Hypertension, R, COVID-19, Heart, Kidney failure, Digital, Pressure, Death, Government, Blood pressure, Degenerative disease, Global Competitiveness Report, BP, Growth, Research, Stroke, Pharmaceutical industry, Medical device, Potash

The blood pressure (BP) monitoring device is a machine that is used to accurately measure the blood pressure of an individual.

Key Points: 
  • The blood pressure (BP) monitoring device is a machine that is used to accurately measure the blood pressure of an individual.
  • Key Questions Answered in This Report:
    How has the global blood pressure monitoring devices market performed so far and how will it perform in the coming years?
  • What is the structure of the global blood pressure monitoring devices industry and who are the key players?
  • What is the degree of competition in the global blood pressure monitoring devices industry?

Fujitsu named to FORTUNE Magazine's 2023 list of "World's Most Admired Companies" for fifth year running

Retrieved on: 
Thursday, February 2, 2023
Fortune (magazine), Magazine, Social responsibility, Quality, Use, Environment, Partnership, Global Competitiveness Report, Organization, ESG, IT service management, Risk management, Korn Ferry, People Management, Quality Capital Management, Fujitsu

TOKYO, Feb 2, 2023 - (JCN Newswire) - Fujitsu today announced that it has been named to FORTUNE Magazine's 2023 list of "World's Most Admired Companies" for the fifth year in a row.

Key Points: 
  • TOKYO, Feb 2, 2023 - (JCN Newswire) - Fujitsu today announced that it has been named to FORTUNE Magazine's 2023 list of "World's Most Admired Companies" for the fifth year in a row.
  • This year, 645 companies were nominated from 27 countries as the "World's Most Admired Companies," of which 324 were selected (12 of which were Japanese companies).
  • Conducted through a partnership between Fortune Magazine and Korn Ferry (1), the annually published "World's Most Admired Companies" list is determined based on a survey of a combined 3,760 executives, directors at global companies, and analysts.
  • Companies that receive high evaluations in these categories are selected for inclusion in the list.

Roman Loosen Joins Fluence as Senior Vice President, Chief Business Operations and Transformation Officer to Oversee Operational Excellence

Retrieved on: 
Tuesday, January 3, 2023
Growth, Roman, Acceleration, Ecosystem, Senior, Global Competitiveness Report, Transformation, Management, Radiant exposure

Loosen joins Fluence from Siemens, where he spent more than 20 years as a change agent, implementing proven business transformation strategies in various roles and countries across the Siemens organization.

Key Points: 
  • Loosen joins Fluence from Siemens, where he spent more than 20 years as a change agent, implementing proven business transformation strategies in various roles and countries across the Siemens organization.
  • “Roman’s demonstrated success as a business transformation and change management expert will help lead Fluence into our next chapter of profitable growth,” said Fluence President and Chief Executive Officer Julian Nebreda.
  • Roman will focus on leading our transformation efforts in the short term and operational excellence in the longer term.”
    Mr.
  • Loosen most recently served as Senior Vice President and Head of the Global Competitiveness program for Siemens Smart Infrastructure.

Global Probiotic Dietary Supplement Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts

Retrieved on: 
Tuesday, January 3, 2023
Inflammatory bowel disease, Reckitt, Immune system, Saccharomyces boulardii, Tablet, Urinary tract infection, Symrise, Herbal, Global Competitiveness Report, COVID-19, Extrapyramidal system, Inflammation, Tooth decay, Coronavirus, Human, R, Irritable bowel syndrome, Food, Prevalence, Immunity, Diarrhea, Probiotic, BioGaia, Capsule, Research, Cancer, ADM (company), Infant, Dietary supplement, Potash, Lactobacillus, Bifidobacterium, Growth

DUBLIN, Jan. 3, 2023 /PRNewswire/ -- The "Probiotic Dietary Supplement Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 3, 2023 /PRNewswire/ -- The "Probiotic Dietary Supplement Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global probiotic dietary supplement market size reached US$ 6.4 Billion in 2021.
  • What has been the impact of COVID-19 on the global probiotic dietary supplement market?
  • What is the structure of the global probiotic dietary supplement market and who are the key players?

Chembio Diagnostics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Amazon, Company, Private Securities Litigation Reform Act, Government, Growth, Hospital, Investment, Sale, DPP, GLOBE, Vertically transmitted infection, Total, Infection, Automation, COVID-19, HIV, Global Competitiveness Report, Research, Adoption, Mission statement, Annual report, U.S. Securities and Exchange Commission, Competition (economics), Clinical trial, Forward-looking statement, Credit agreements in South Africa, Direct, Investor relations, Technology, Classification, Diagnosis, Policy, United Kingdom, Efficiency, Video game, Natural gas, Vaccine, Pharmaceutical industry, Bank

HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio or the Company) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio or the Company) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022.
  • Gross product margin for the third quarter of 2022 was $1.2 million, compared to $1.5 million for the prior year period.
  • Cash and cash equivalents as of September 30, 2022 totaled $21.1 million, compared to $22.8 million at June 30, 2022.
  • Chembio will host a conference call today beginning at 4:30 pm ET to discuss its financial results and recent business highlights.

BRG APPOINTS LEADING COMPETITION EXPERT AS VICE-CHAIRMAN

Retrieved on: 
Wednesday, September 21, 2022
President Clinton, National academy, Supreme Court of the United States, Policy, Council of Economic Advisers, Name, Deepwater Horizon, BRG, Economics, Uwe Sunde, News, Council of Economic Advisers (Scotland), Telecommunication, Thomas, United States Environmental Protection Agency, Business, PFAS, Technology, Global Competitiveness Report, Transport, National, Polychlorinated biphenyl, TCP, UC, Science, Science Advisory Board, Graduate school, Congress, Haas School of Business, University, Hostile witness, University of California, Berkeley, Council, Berkeley Research Group, Management, Teece

Immediately prior to joining BRG, he was president of a leading global economic consulting firm.

Key Points: 
  • Immediately prior to joining BRG, he was president of a leading global economic consulting firm.
  • Sunding has consulted and testified in cases related to competition in industries such as software applications, credit cards and agricultural products.
  • Sunding's initial focus at BRG will include growing the firm's successful international competition economics offering into a world-leading practice.
  • Twelve of its experts are profiled in Who's Who Legal Competition , and the firm is ranked in the Global Competition Review 100, Global Competition Review Economics 23 and as Band1 in Chambers Litigation Support: Economic Analysts.

Chembio Diagnostics Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
U.S. Securities and Exchange Commission, Global Competitiveness Report, Adoption, Investor relations, United Kingdom, Competitive programming, Forward-looking statement, GLOBE, Diagnosis, Technology, Private Securities Litigation Reform Act, Growth, Clinical trial, Investment, Policy, Direct, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Infection, Hospital, Classification, Annual report, Credit, DPP, Government, Credit agreements in South Africa, COVID-19, Company, Mission statement, LP, Â, Automation, Research, HIV, Vertically transmitted infection, Total, Efficiency, Video game, Pharmaceutical industry, Renewable energy, Online gambling, Vaccine, Bank

HAUPPAUGE, N.Y., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio or the Company) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2022.

Key Points: 
  • HAUPPAUGE, N.Y., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio or the Company) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2022.
  • Gross product margin for the second quarter of 2022 was $0.8 million, compared to negative $0.1 million for the prior year period.
  • Gross product margin percentage for the second quarter of 2022 was 9%, compared to negative 3% for the prior year period.
  • Gross product margin improvement in the second quarter of 2022 was driven by product mix and operational productivity.

Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors

Retrieved on: 
Tuesday, May 24, 2022
Senior, Forecasting, Vertically transmitted infection, Infection, Treasurer of Australia, Hematology, COVID-19, Competition (economics), Accounting, Â, Government, Board, Treasurer, Hospital, Technology, Board of directors, DPP, Shareholder, Acquisition, Global Competitiveness Report, Controller, GLOBE, Medical device, Management, Finance

HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq:CEMI), aleading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembios 2022 Annual Meeting of Stockholders.

Key Points: 
  • HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq:CEMI), aleading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembios 2022 Annual Meeting of Stockholders.
  • We are excited to have Leslie join the Chembio Board of Directors, said Richard Eberly, Chembios Chief Executive Officer and President.
  • Ms. Teso-Lichtman serves as Senior Vice President and Chief Financial Officer of CereVasc, Inc., where she is responsible for the accounting, finance, and treasury functions, including forecasting and capital planning.
  • I am thrilled to join the Chembio Board of Directors as the true value of point-of-care diagnostics has been realized and elevated in the global healthcare system, said Ms. Teso-Lichtman.

Chembio Diagnostics Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Forward-looking statement, Credit agreements in South Africa, Population, Mission statement, Private Securities Litigation Reform Act, Investment, Automation, U.S. Securities and Exchange Commission, GLOBE, Policy, Company, Global Competitiveness Report, SARS-COV-2, Â, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Research, Vertically transmitted infection, DPP, Built-in self-test, Government, Clinical trial, HIV, Diagnosis, Annual report, Investor relations, Hospital, Uncertainty, Efficiency, Classification, Credit, Infection, Pharmacy, Creditor, Technology, Growth, COVID-19 testing, Market, Video game, Pharmaceutical industry, Vaccine, Risk management

HAUPPAUGE, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio or the Company) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2022.

Key Points: 
  • HAUPPAUGE, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio or the Company) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2022.
  • Gross product margin for the first quarter of 2022 was $3.3 million, compared to $0.5 million for the prior year period.
  • Gross product margin percentage for the first quarter of 2022 was 18%, compared to 12% for the prior year period.
  • Chembio will host a conference call today beginning at 4:30 pm ET to discuss its financial results and recent business highlights.

Care Angel Continues Leadership Team Expansion Welcoming Mike Twigg as Chief Revenue Officer and Executive Vice President of Global Sales

Retrieved on: 
Thursday, February 10, 2022
Global Competitiveness Report, Automation, Industry, Solution, Triage, University, AI, BS, Wolters Kluwer, The Economist, Patient, Management, Medicine, Psychology

MIAMI, Feb. 10, 2022 /PRNewswire/ -- Care Angel , the leader in digital health engagement and collaboration using AI and voice nurse assistant technology, today announced the appointment of Mike Twigg as chief revenue officer and executive vice president of global sales.

Key Points: 
  • MIAMI, Feb. 10, 2022 /PRNewswire/ -- Care Angel , the leader in digital health engagement and collaboration using AI and voice nurse assistant technology, today announced the appointment of Mike Twigg as chief revenue officer and executive vice president of global sales.
  • Mr. Twigg brings to the position over 32 years of experience leading and mentoring teams and driving substantial growth in client asset size and annual revenue.
  • The Care Angel team is looking forward to building off those achievements as we go to the next level."
  • Care Angel is the industry leader in automation and exponentially scalable solutions for continuous engagement, management, surveillance, triage, navigation and care of millions.